At a glance

ClinicalIndex Comparison Record

Phase 3Completed

Drug / intervention

Duloxetine +2 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00122850

NCT00122850Phase 3Completed

A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder.

Eli Lilly and Company·interventional·Posted Jul 22, 2005·Updated Nov 6, 2007

In Brief

A Phase 3 clinical trial evaluating Duloxetine, venlafaxine, and 1 other intervention for Anxiety Disorders. Completed, across 19 sites.

This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesUnited States

Phase 3CompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartOct 2004

First PostedJul 2005

Study CompletionNov 2005

TodayJul 2026

First PostedJul 22, 2005

Enrollment StartOct 1, 2004

Study CompletionNov 1, 2005

TodayJul 2, 2026

Posted 20.9 years ago

Duloxetinedrug

venlafaxinedrug

placebodrug